Trial reportSignal transduction and targeted therapy2026
Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial.
Trial report in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02125240 (Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This multi-center, double-blind, placebo-controlled, randomized phase 3 trial (ICWIP) assessed the efficacy and safety of 3-year icotinib adjuvant treatment versus placebo in patients with completely resected stage II-IIIA epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma who had completed four cycles of adjuvant chemotherapy (NCT02125240). Eligible patients were randomly assigned 1:1 to receive either icotinib (125 mg, three times daily) or placebo for 3 years. The primary endpoint was independent review committee (IRC)-assessed disease-free survival (DFS). Between June 3, 2014, and November 15, 2018, 66 patients received icotinib, and 69 patients received placebo. At the data cutoff date of October 31, 2024, the median follow-up for DFS was 78.3 months (interquartile range [IQR] 71.3-95.6) for the icotinib group and 69.9 months (IQR 35.2-96.4) for the placebo group. IRC-assessed median DFS was 48.2 months (95% confidence interval [CI] 33.0-63.4) in the icotinib group and 20.0 months (95% CI 14.7-32.9) in the placebo group (hazard ratio [HR] 0.54, 95% CI 0.34-0.87; p = 0.011). The 3-year DFS rates were 58.5% (95% CI 39.9-73.1%) for the icotinib group and 36.1% (95% CI 19.9-52.6%) for the placebo group, and the 5-year DFS rates were 39.4% (95% CI 22.2-56.2%) for the icotinib group and 25.8% (95% CI 8.7-47.1%) for the placebo group. The median overall survival (OS) was not reached in either group (HR 0.84, 95% CI 0.39-1.81; p = 0.65). The estimated 5-year OS rates were 88.6% (95% CI 57.9-97.5%) for the icotinib group and 83.4% (95% CI 57.7-94.2%) for the placebo group. Treatment-related adverse events occurred in 48.5% (32/66) and 23.2% (16/69) of the patients in the icotinib group and the placebo group, respectively. Three-year adjuvant treatment with icotinib significantly improved DFS compared to placebo in patients with completely resected stage II-IIIA EGFR-mutated lung adenocarcinoma who had completed four cycles of adjuvant chemotherapy, with a manageable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.